RxDoctor Payments Data

Daniel Kessler, MD

Ophthalmology · Torrington, CTNPI 1952330391

Payments from drug & device makers

$870in general payments, 2019–2025

Across 22 payments — averaging $39.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$243
  • Bausch & Lomb Americas Inc.$209
  • AbbVie$160
  • Tarsus Pharmaceuticals, Inc.$103
  • Merck$72
  • Aerie Pharmaceuticals, Inc.$36
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870 in reported general payments places this provider in the 45th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$164,155
Medicare patients
608
Services billed
1,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost44$21,744
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol62$11,323
Cyclosporine38$8,561
RocklatanNetarsudil Mesylat/Latanoprost11$6,587
Timolol Maleate56$5,046
SimbrinzaBrinzolamide/Brimonidine Tart17$3,459
Latanoprost350$2,901
Travoprost14$2,157
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat97$1,740
Prednisolone Acetate59$1,246
ValacyclovirValacyclovir Hcl13$791
Ketorolac Tromethamine30$466
Fluorometholone14$272
Ofloxacin31$259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$160$21,74444 claims
Aerie Pharmaceuticals, Inc.Rocklatan$36$6,58711 claims
AlconSimbrinza$243$3,45917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →